A20-a bipartite ubiquitin editing enzyme with immunoregulatory potential

Advances in Experimental Medicine and Biology

Volumn 809, Issue , 2014, Pages 1-12

  Wertz, Ingrid ^a   Dixit, Vishva ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION PROTEIN 1; PROTEIN KINASE; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UBIQUITIN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN;

APOPTOSIS; B LYMPHOCYTE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; UBIQUITINATION; ZINC FINGER MOTIF; IMMUNE SYSTEM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

DNA-BINDING PROTEINS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-KAPPA B; NUCLEAR PROTEINS; UBIQUITIN;

EID: 84908028738     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0398-6_1     Document Type: Chapter

References (83)

1. McCulloch CA, Downey GP, El-Gabalawy H. Signalling platforms that modulate the inflammatory response: new targets for drug development. Nat Rev Drug Discov 2006; 5:864-76; PMID: 17016427; http://dx.doi. orgll 0.1 038/nrd21 09.
2. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
3. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006; 2006:reI3; PMID: 17047224; http://dx.doi.orgIl0.1126/stke.3572006re13.
4. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
5. Dixit VM, Green S, Sarma V, Holzman LB, WolfFW, O' Rourke K, Ward PA, Prochownik EV, Marks RM. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specitic chemotaxin. J Bioi Chern 1990; 265:2973-8; PMID:2406243.
6. Krikos A, Laherty CD, Dixit VM. Transcriptional activation ofthe tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Bioi Chern 1992; 267:17971-6; PMID:1381359.
7. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Bioi 2005; 7:758-65; PMID:16056267; http://dx.doi.orglI0.1038/ncb0805-758.
8. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C. A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. J Bioi Chern 1996; 271: 18068-73; PMID:8663499; http://dx.doi.org/l 0.1 074/jbc.271.30.18068.
9. Jaattela M, Mouritzen H, Elling F, Bastholm L. A20 zinc finger protein inhibits TNF and IL-l signaling. J Immunol1996; 156:1166-73; PMID:8557994.
10. Longo CR, Arvelo MB, Patel VI, Daniel S, Mahiou J, Grey ST, Ferran C. A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Circulation 2003; 108:1113-8; PMID:12885753; http://dx.doi.orgIl0.1161101.CIR.0000083718.76889.DO.
11. II. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
12. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
13. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
14. Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE, Lee BL, Shiffin N, Advincula R, Malynn BA, The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 2008; 28:381-90; PMID:18342009; http://dx.doi.orgIl0.1016/j. immuni.2008.02.002.
15. Laherty CD, Perkins ND, Dixit VM. Human T cell leukemia virus type I Tax and phorbol 12-myristate 13-acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor kappa B. J Bioi Chern 1993; 268:5032-9; PMID:8444879.
16. Heyninck K, Beyaert R. The cytokine-inducible zinc tinger protein A20 inhibits IL-I-induced NF-kappaB activation at the level ofTRAF6. FEBS Lett 1999; 442: 147-50; PMID:9928991; http://dx.doi.orgIl0.1016/SOOI4-5793(98)01645-7.
17. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
18. Ferran C. Protective genes in the vessel wall: Modulators of graft survival and function. Transplantation 2006; 82(Suppl):S36-40; PMID: 16829794; http://dx.doi.orgIl0.1097/01.lp.0000231445.62162.d5.
19. Daniel S, Arvelo MB, Patel VI, Longo CR, Shrikhande G, Shukri T, Mahiou J, Sun DW, Mottley C, Grey ST, et a!. A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. Blood 2004; 104:2376-84; PMID:15251990; http://dx.doi.orgllO.l182/blood-2003-02-0635.
20. Arvelo MB, Cooper JT, Longo C, Daniel S, Grey ST, Mahiou J, Czismadia E, Abu-Jawdeh G, Ferran C. A20 protects mice trom D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology 2002; 35:535-43; PMID: 11870365.
21. Grey ST, Longo C, Shukri T, Patel VI, CsizmadiaE, Daniel S, ArveloMB, Tchipashvili V, Ferran C. Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. J Immunol 2003; 170:6250-6; PMID:12794157.
22. Opipari A W Jr., Boguski MS, Dixit VM. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Bioi Chern 1990; 265:14705-8; PMID:2118515.
23. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
24. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
25. Evans PC, Ovaa H, Hamon M, Kilshaw P J, Hannn S, Bauer S, Ploegh HL, Smith TS. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J 2004; 378:727-34; PMTD: 14748687; http://dx.doi.orgIl0.l042/BJ20031377.
26. Evans PC, Smith TS, Lai MJ, Williams MG, Burke DF, Heyninck K, Kreike MM, Beyaert R, Blundell TL, Kilshaw PJ. A novel type of deubiquitinating enzyme. J BioI Chern 2003; 278:23180-6; PMTD:12682062; http://dx.doi.org/I 0.1 07 4/jbc.M30 1863200.
27. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
28. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
29. Pickart CM. Mechanisms underlyingubiquitination. Annu Rev Biochem 2001; 70:503-33; PMTD:11395416; http://dx.doi.org/10.1146/annurev.biochem. 70.1.503.
30. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell BioI 2001; 2:169-78; PMlD: 11265246; http://dx.doi.org/10.1038/35056563.
31. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012; 81:203-29; PMlD:22524316; http://dx.doi.orgll 0.1 I 46/annurev-biochem-0603 I 0-170328.
32. Shi CS, Kehrl JH. Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A1TNF receptor-associated factor 2 (TRAF2). J BioI Chern 2003; 278:15429-34; PMTD:12591926; http://dx.doi. org/IO.l074/jbc.M21 1796200.
33. Balakirev MY, Tchemiuk SO, Jaquinod M, Chroboczek J. Otubains: a new family of cysteine proteases in the ubiquitin pathway. EMBO Rep 2003; 4:517-22; PMlD:12704427; http://dx.doi.org/IO.1038/sj.embor. embor824.
34. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
35. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu 0, et a!. The ubiquitin-modifYing enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5:1052-60; PMTD: 15334086; http://dx.doi.orgIl0.l038/nilll0.
36. Mauro C, Pacifico F, Lavorgna A, Mellone S, Iannetti A, Acquaviva R, Formisano S, Vito P, Leonardi A. ABlN-l binds to NEMOIlKKganlllla and co-operates with A20 in inhibiting NF-kappaB. J Bioi Chem 2006; 281: 18482-8; PMTD: 16684768; http://dx.doi.org/l 0.1 074/jbc.M601502200.
37. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
38. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
39. Lee S, Tsai YC, Mattera R, Smith WJ, Kostelansky MS, Weissman AM, Bonifacino JS, Hurley JH. Structural basis for ubiquitin recognition and autoubiquitination by Rabex-5. Nat Struct Mol BioI 2006; 13:264-71; PMlD: 16462746; http://dx.doi.org/10.1038/nsmbl064.
40. Penengo L, Mapelli M, Murachelli AG, Confalonieri S, Magri L, Musacchio A, Di Fiore PP, Polo S, Schneider TR. Crystal structure of the ubiquitin binding domains of rabex-5 reveals two modes of interaction with ubiquitin. Cell 2006; 124:1183-95; PMTD:16499958; http://dx.doi.org/l0.l016/j.ceI1.2006.02.020.
41. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
42. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
43. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
44. Park SM, Y oon JB, Lee TH. Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAPI and c-IAP2) in vitro. FEBS Lett 2004; 566:151-6; PMlD:I5147886; http://dx.doi. org/l 0.1 016!j.febslet.2004.04.021.
45. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
46. Shembade N, Harhaj E. A20 inhibition OfNFKB and inflammation: targetingE2:E3 ubiquitin enzyme complexes. Cell Cycle 2010; 9:2481-2; PMTD:20543575; http://dx.doi.org/IO.4161/cc.9.13.12269.
47. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
48. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
49. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
50. Shembade N, Harhaj EW. Regulation ofNF-kappaB signaling by the A20 deubiquitinase. Cell Mol Tmmunol 2012; 20: 123-30; PMlD:22343828; http://dx.doi.orgIl0.1038/cmi.2011.59.
51. Shembade N, Pujari R, Harhaj NS, Abbott DW, Harhaj EW. The kinase TKKa inhibits activation of the transcription factor NF-KB by phosphorylating the regulatory molecule TAXIBPI. Nat Immunol 2011; 12:834-43; PMlD:21765415; http://dx.doi.org/10.1038/ni.2066.
52. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
53. ShembadeN, Harhaj NS, Liebl DJ, Harhaj EW. Essential role forTAXIBPI in the terrnination ofTNF-alpha-, TL-l-and LPS-mediated NF-kappaB and JNK signaling. EMBO J 2007; 26:3910-22; PMTD:I7703191; http://dx.doi.org/10.1 038!sj.emboj. 7601823.
54. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
55. Skaug B, Chen J, Du F, He J, Ma A, Chen ZJ. Direct, noncatalytic mechanism ofTKK inhibition by A20. Mol Cell 2011; 44:559-71; PMlD:22099304; http://dx.doi.org/10.1016/j.moicel.2011.09.015.
56. Tokunaga F, Nishimasu H, Tshitani R, Goto E, Noguchi T, Mio K, Kamei K, Ma A, Twai K, Nureki O. Specitic recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-KB regulation. EMBO J 2012; 31:3856-70; PMlD:23032187; http://dx.doi.org/l0.l038/emboj.2012.241.
57. Verhelst K, Carpentier I, Kreike M, Meloni L, Verstrepen L, Kensche T, Dikic I, Beyaert R. A20 inhibits LUBAC-mediated NF-KB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J 2012; 31:3845-55; PMlD:23032186; http://dx.doi.org/l0.l038/emboj.2012.240.
58. Lu TT, Onizawa M, Hammer GE, Turer EE, Yin Q, Damko E, Agelidis A, Shifrin N, Advincula R, Barrera J, et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 2013; 38:896-905; PMlD:23602765; http://dx.doi.org/l0.l016/j.immuni.2013.03.008.
59. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
60. Coomaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R. T cell antigen receptor stimulation induces MALT 1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Tmmunol 2008; 9:263-71; PMlD: 18223652; http://dx.doi.org/l0.l038/niI561.
61. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
62. Siracuse JJ, Fisher MD, da Silva CG, Peterson CR, Csizmadia E, Moll HP, Damrauer SM, Studer P, Choi L Y, Essayagh S, et al. A20-mediated modulation of inflammatory and immune responses in aortic allografts and development oftransplant arteriosclerosis. Transplantation 2012; 93:373-82; PMTD:22245872; http://dx.doi.org/l 0.1 097!TP.ObOI3e3182419829.
63. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
64. Damrauer SM, Fisher MD, Wada H, Siracuse n, da Silva CG, Moon K, Csizmadia E, Maccariello ER, Patel VI, Studer P, et al. A20 inhibits post-angioplasty restenosis by blocking macrophage trafficking and decreasing adventitial neovascularization. Atherosclerosis 201 0; 211:404-8; PMTD:20430393; http://dx.doi. orgll 0.1 0 16/j.atherosclerosis.20 I 0.03.029.
65. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
66. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
67. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, Seto M. TNF AIP31A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114:2467-75; PMID: 19608751; http://dx.doi.orgll0.1182Iblood-2008-12-194852.
68. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
69. Braun FC, Grabarczyk P, Mobs M, Braun FK, Eberle J, Beyer M, Sterry W, Busse F, SchrOder J, Delin M, et al. Tumor suppressor TNF AIP3 (A20) is frequently deleted in Sezary syndrome. Leukemia 2011; 25: 1494-501; PMlD:21625233; http://dx.doi.orgIl0.1038/leu.2011.l01.
70. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
71. Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, et al. The NF-kappaB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009; 113:4918-21; PMTD:I9258598; http:// dx.doi.orgllO.l 182Iblood-2008-08-174 I I O.
72. Hymowitz SG, Wertz TE. A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer 201 0; 10:332-41; PMlD:20383 180; http://dx.doi.orgllO.1038/nrc2775.
73. Vereecke L, Beyaert R, van Loo G. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans 2011; 39: 1086-91; PMlD:21787353; http://dx.doi.orgll0.l042/ BST0391086.
74. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
75. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
76. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
77. Elsby LM, Orozco G, Denton J, Worthington J, Ray DW, Donn RP. Functional evaluation ofTNF AIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol20 10; 28:708-14; PMlD:208227I O.
78. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, Pe' er I, Burtt NP, Blumenstiel B, DeFelice M, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007; 39:1477-82; PMlD:17982456; http://dx.doi.orgll0.1038/ng.2007.27.
79. Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J, Donn R, Symmons D, Hider S, Bruce IN, et al.; Wellcome Trust Case Control Consortium; YEAR Consortium. Rheumatoid arthritis association at 6q23. Nat Genet 2007; 39:1431-3; PMTD:17982455; http://dx.doi.orgll0.l038/ng.2007.32.
80. Lin R, Yang L, Nakhaei P, Sun Q, Sharif-Askari E, Julkunen I, HiscottJ. Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J Bioi Chern 2006; 281:2095-103; PMTD: 16306043; http://dx.doi.orgIl0.l074/jbc.M510326200.
81. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
82. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol2005; 5:941-52; PMID:16322747; http://dx.doi.orgllO.l038/nriI731.
83. da Silva CG, Maccariello ER, Wilson SW, Putheti P, Daniel S, Damrauer SM, Peterson CR, Siracuse n, Kaczmarek E, Ferran C. Hepatocyte growth factor preferentially activates the anti-inflammatory arm of NF-KB signaling to induce A20 and protect renal proximal tubular epithelial cells from inflammation. J Cell Physiol2012; 227:1382-90; PMlD:21618526; http://dx.doi.orgIl0.1002/jcp.22851.